{ALCLS FP Equity DES <GO>}
MORE: Pfizer to Buy ~10% Cellectis Stake at 49% Premium
2014-06-18 05:56:04.785 GMT
By Jurjen van de Pol
June 18 (Bloomberg) -- Pfizer to buy newly issued shares at
EU9.25 vs EU6.20/shr closing price.
* Needs approval by two-thirds of voting Cellectis
shareholders
* Says Cellectis shareholders representing 52.8% of voting
rights already voted in favor
* Pfizer may terminate collaboration agreement if equity sale
isn’t approved
* Cellectis expects to open U.S. site to work with Pfizer
* NOTE today: Pfizer, Cellectis to Develop Cancer CAR-T
Immunotherapy {NSN N7CM5L6JTSES <go>}
Link to Statement:{NSN N7CLW0MEQTXG <GO>}
Link to Company News:{ALCLS FP <Equity> CN <GO>}
Link to Company News:{PFE US <Equity> CN <GO>}
For Related News and Information:
First Word scrolling panel: {FIRST<GO>}
First Word newswire: {NH BFW<GO>}
To contact the reporter on this story:
Jurjen van de Pol in Frankfurt at +49-69-9204-1104 or
jvandepol@bloomberg.net
To contact the editor responsible for this story:
James Ludden at +44-20-7673-2645 or
jludden@bloomberg.net
2014-06-18 05:56:04.785 GMT
By Jurjen van de Pol
June 18 (Bloomberg) -- Pfizer to buy newly issued shares at
EU9.25 vs EU6.20/shr closing price.
* Needs approval by two-thirds of voting Cellectis
shareholders
* Says Cellectis shareholders representing 52.8% of voting
rights already voted in favor
* Pfizer may terminate collaboration agreement if equity sale
isn’t approved
* Cellectis expects to open U.S. site to work with Pfizer
* NOTE today: Pfizer, Cellectis to Develop Cancer CAR-T
Immunotherapy {NSN N7CM5L6JTSES <go>}
Link to Statement:{NSN N7CLW0MEQTXG <GO>}
Link to Company News:{ALCLS FP <Equity> CN <GO>}
Link to Company News:{PFE US <Equity> CN <GO>}
For Related News and Information:
First Word scrolling panel: {FIRST<GO>}
First Word newswire: {NH BFW<GO>}
To contact the reporter on this story:
Jurjen van de Pol in Frankfurt at +49-69-9204-1104 or
jvandepol@bloomberg.net
To contact the editor responsible for this story:
James Ludden at +44-20-7673-2645 or
jludden@bloomberg.net